Propel Family Products
Intersect Ent. · Decision date Sep 23, 2026
What did the FDA approve?
The FDA recorded an approval dated 2026-09-23 for supplement P100044/S060, submitted by Intersect Ent. under the Propel Family Products. The supplement's stated purpose is a shelf-life extension from 24 months to 36 months, filed as a real-time process supplement with the reason given as a labeling change covering indications, instructions, shelf life or tradename. The product category listed is a drug-eluting sinus stent in the ear, nose and throat specialty, product code OWO.
That approval modifies the terms of the existing P100044 PMA; it is not a new approval of the whole system. The database does not state what evidence supported the extension, what the stent's original indications were, or what labeling text changed, so those details remain unknown. The source statement reports a purpose set by the applicant, which does not by itself establish safety or clinical effectiveness.
FDA approval order statement
Approval for a shelf-life extension of the Propel Family Products from 24 months to 36 months
- Regulatory pathway
- PMA supplement
- Supplement type
- Real-Time Process
- Clinical specialty
- Ear, Nose, Throat
- Decision date
- Sep 23, 2026
- FDA change category
- Labeling Change - Indications/instructions/shelf life/tradename
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P100044/S060
- Regulatory pathway
- PMA supplement
- Applicant
- Intersect Ent.
- Product code
- OWO
- Decision code
- APPR
- Decision date
- Sep 23, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Drug-eluting sinus stent.
- Applicant
- Intersect Ent.
- Product code
- OWO
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P100044. Subsequent supplements may change the device or its indications.
FDA decision timeline
P100044 · Original PMA
PROPEL
P100044/S060 received
Application receipt date recorded by FDA.
P100044/S060 · FDA decision
Real-Time Process
Timeline entries are records held by MedtechLedger for P100044. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P100044
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
PROPELP100044 | Intersect Ent. | PMA approval | Aug 11, 2011 | FDA |
PROPELP100044/S061 | Intersect Ent. | PMA supplement | Sep 22, 2026 | FDA |
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
FDA describes the real-time supplement process as a review route for minor changes to a device, including certain design, software, sterilization or labeling changes.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Intersect Ent.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 1555 Adams Dr., Menlo Park, CA, 94025
Sources and methodology
- Original FDA record: P100044/S060
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records
